Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Systematic Review Article

Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice

Author(s): Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso*, Valentin Skryabin, Stefano L. Sensi and Massimo Di Giannantonio

Volume 28, Issue 27, 2022

Published on: 12 August, 2022

Page: [2241 - 2259] Pages: 19

DOI: 10.2174/1381612828666220623092853

Price: $65

Abstract

Background: Concurrent disorder or dual diagnosis refers to a combination of substance use disorders and mental disorders that occur in the same patient simultaneously. These conditions pose significant clinical and healthcare impacts and are often underdiagnosed, undertreated, and complex to manage.

Objective: We assessed the quality of current pharmacological recommendations for the management of dual diagnosis, particularly by evaluating the use of second-generation antipsychotics (SGA).

Methods: A literature search was performed using the PubMed and Scopus databases for publications up to September 21, 2021, without any time restrictions. The following search strings were used: (aripiprazole OR brexpiprazole OR cariprazine OR paliperidone OR risperidone OR quetiapine OR clozapine OR olanzapine) AND (psychosis OR schizophrenia OR schizoaffective) AND (“substance use disorder” OR cocaine OR alcohol OR cannabis OR heroin OR “double diagnosis” OR “dual diagnosis”)) NOT (animal OR rat OR mouse) NOT (review or meta-analysis).

Results: The search produced a final set of 41 articles. Most patients were males and were affected by schizophrenia, with cannabis the most abused substance, followed by alcohol. Aripiprazole was the most used drug, either orally or by long-acting formulations, followed by risperidone with oral and long-acting formulations, clozapine, olanzapine, and quetiapine.

Conclusion: The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and longacting injectable antipsychotics.

Keywords: Antipsychotic drugs, dual diagnosis, dual disorders, substance use disorder, first-generation antipsychotic, second-generation antipsychotic.

[1]
National Institute For Health And Care Guideline scope Severe mental illness and substance misuse (dual diagnosis): Community health and social care services. 2016 pp. 1-14.
[2]
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Co-morbid substance use and mental disorders in Europe: A review of the data 2013 pp. 1-12.
[3]
Adan Ana BI. Comorbidity between substance use disorder and severe mental illness.In: Dual Diagnosis, Neuropathology of Drug Addictions and Substance Misuse General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions. Academic Press 2016; pp. 258-68.
[http://dx.doi.org/10.1016/B978-0-12-800634-4.00026-3]
[4]
Vitali M, Mistretta M, Alessandrini G, et al. Pharmacological treatment for dual diagnosis: A literature update and a proposal of intervention. Riv Psichiatr 2018; 53(3): 160-9.
[PMID: 29912219]
[5]
Hryb K, Kirkhart R, Talbert R. A call for standardized definition of dual diagnosis. Psychiatry (Edgmont) 2007; 4(9): 15-6.
[6]
Martinotti G, Barlati S, Prestia D, et al. Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release. Psychopharmacology 2020; 237(11): 3497-501.
[http://dx.doi.org/10.1007/s00213-020-05644-3]
[7]
Chiappini S, Guirguis A, John A, Corkery JM, Schifano F. COVID-19: The hidden impact on mental health and drug addiction. Front Psychiatry 2020; 11: 767.
[http://dx.doi.org/10.3389/fpsyt.2020.00767] [PMID: 32848937]
[8]
Singh Balhara YP, Szerman N, Singh S, et al. Treatment needs and service delivery for patients with dual disorders during the covid-19 pandemic: Findings from the WADD survey. J Dual Diagn 2021; 17(3): 248-56.
[http://dx.doi.org/10.1080/15504263.2021.1940413] [PMID: 34165030]
[9]
Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addict Behav 1998; 23(6): 717-34.
[http://dx.doi.org/10.1016/S0306-4603(98)00073-2] [PMID: 9801712]
[10]
American Psychiatric Association DS. Diagnostic And Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: American psychiatric association 2013.
[11]
United Nations Office on Drugs and Crime (UNODC). Informal scientific network statement managing psychiatric comorbidities in drug use disorders 2020.
[12]
Molloy R, Munro I, Pope N. Understanding the experience of diagnostic overshadowing associated with severe mental illness from the consumer and health professional perspective: A qualitative systematic review protocol. JBI Evid Synth 2020; 19(6): 1362-8.
[http://dx.doi.org/10.11124/JBIES-20-00244] [PMID: 33165171]
[13]
Shefer G, Henderson C, Howard LM, Murray J, Thornicroft G. Diagnostic overshadowing and other challenges involved in the diagnostic process of patients with mental illness who present in emergency departments with physical symptoms--a qualitative study. PLoS One 2014; 9(11): e111682.
[http://dx.doi.org/10.1371/journal.pone.0111682] [PMID: 25369130]
[14]
Volkow ND, Torrens M, Poznyak V, et al. Managing dual disorders: A statement by the Informal Scientific Network, UN Commission on Narcotic Drugs. World Psychiatry 2020; 19(3): 396-7.
[http://dx.doi.org/10.1002/wps.20796] [PMID: 32931124]
[15]
Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19): 2511-8.
[http://dx.doi.org/10.1001/jama.1990.03450190043026] [PMID: 2232018]
[16]
Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: Results of the International Consortium in Psychiatric Epidemiology. Addict Behav 1998; 23(6): 893-907.
[http://dx.doi.org/10.1016/S0306-4603(98)00076-8] [PMID: 9801724]
[17]
Han B, Compton WM, Blanco C, Colpe LJ. Prevalence, treatment, and unmet treatment needs of US adults with mental health and substance use disorders. Health Aff (Millwood) 2017; 36(10): 1739-47.
[http://dx.doi.org/10.1377/hlthaff.2017.0584] [PMID: 28971918]
[18]
Charzynska K, Hyldager E, Baldacchino A, et al. Comorbidity patterns in dual diagnosis across seven European sites. Eur J Psychiatry 2011; 25(4): 179-91.
[http://dx.doi.org/10.4321/S0213-61632011000400001]
[19]
Martinotti G, De Risio L, Schifano F, Pettorruso M, Vannini C. Substance related exogenous psychosis: A post-modern syndrome. CNS Spectr 2021; 26(1): 84-91.
[20]
Orsolini L, Chiappini S, Papanti D, De Berardis D, Corkery JM, Schifano F. The bridge between classical and ‘synthetic’/chemical psychoses: Towards a clinical, psychopathological and therapeutic perspective. Front Psychiatry 2019; 10: 851.
[http://dx.doi.org/10.3389/fpsyt.2019.00851] [PMID: 31849723]
[21]
Schifano F, Napoletano F, Chiappini S, et al. New/emerging psychoactive substances and associated psychopathological consequences. Psychol Med 2021; 51(1): 30-42.
[22]
Ricci V, Ceci F, Di Carlo F, et al. Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug Alcohol Depend 2021; 229: 109118.
[23]
Emma C. Public Health England. Better care for people with co-occurring mental health, and alcohol and drug use conditions. London, England. Public Health 2017; pp. 66.
[24]
Hakobyan S, Vazirian S, Lee-Cheong S, Krausz M, Honer WG, Schutz CG. Concurrent disorder management guidelines. Systematic review. J Clin Med 2020; 9(8): 1-16.
[http://dx.doi.org/10.3390/jcm9082406] [PMID: 32731398]
[25]
Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr Opin Psychiatry 2012; 25(3): 194-200.
[http://dx.doi.org/10.1097/YCO.0b013e328351a3e0] [PMID: 22395768]
[26]
Murthy P, Mahadevan J, Chand PK. Treatment of substance use disorders with co-occurring severe mental health disorders. Curr Opin Psychiatry 2019; 32(4): 293-9.
[http://dx.doi.org/10.1097/YCO.0000000000000510] [PMID: 31157674]
[27]
Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: Results from a pilot study. J Clin Psychopharmacol 2007; 27(5): 519-20.
[http://dx.doi.org/10.1097/JCP.0b013e318150c841] [PMID: 17873691]
[28]
Price SA, Brahm NC. Antipsychotic treatment of adolescent dual diagnosis patients. J Pediatr Pharmacol Ther 2011; 16(4): 226-36.
[http://dx.doi.org/10.5863/1551-6776-16.4.226] [PMID: 22768007]
[29]
Temmingh HS, Amos T, Siegfried N, Stein DJ. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database Syst Rev 2014; 2014(4): CD011057.
[http://dx.doi.org/10.1002/14651858.CD011057] [PMID: 29355909]
[30]
Grau-López L, Roncero C, Daigre C, et al. Observational study on medications prescribed to dual-diagnosis outpatients. J Addict Med 2014; 8(2): 84-9.
[http://dx.doi.org/10.1097/ADM.0000000000000024] [PMID: 24562401]
[31]
Grau-López L, Szerman N, Torrens M, et al. Professional perception of clozapine use in patients with dual psychosis. Actas Esp Psiquiatr 2020; 48(3): 99-105.
[PMID: 32905602]
[32]
Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008; 23(5): 417-24.
[http://dx.doi.org/10.1002/hup.944] [PMID: 18425995]
[33]
Clerici M, de Bartolomeis A, De Filippis S, et al. Patterns of management of patients with dual disorder (Psychosis) in Italy: A survey of psychiatrists and other physicians focusing on clinical practice. Front Psychiatry 2018; 9: 575.
[http://dx.doi.org/10.3389/fpsyt.2018.00575] [PMID: 30483161]
[34]
Abdel-Baki A, Thibault D, Medrano S, et al. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Early Interv Psychiatry 2020; 14(1): 69-79.
[http://dx.doi.org/10.1111/eip.12826] [PMID: 31125513]
[35]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[36]
Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998; 15(2): 113-6.
[http://dx.doi.org/10.1016/S0740-5472(97)00134-7] [PMID: 9561949]
[37]
Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol 2007; 27(5): 514-6.
[http://dx.doi.org/10.1097/JCP.0b013e31814cfaa9]
[38]
Desseilles M, Mathot F, Desseilles M. Aripiprazole diminishes cannabis use in schizophrenia. J Neuropsychiatry Clin Neurosci 2008; 20: 117-8.
[http://dx.doi.org/10.1176/jnp.2008.20.1.117]
[39]
Erdogan A, Kulaksizoglu B, Bingol MS, Cinemre B, Kuloglu MM. Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder. Dusunen Adam 2021; 34(1): 102-6.
[http://dx.doi.org/10.14744/DAJPNS.2021.00126]
[40]
Feeley RJ, Arnaout B, Yoon G. Effective switch from clozapine to aripiprazole in treatment-resistant schizophrenia and comorbid alcohol use disorder. J Clin Psychopharmacol 2017; 37(6): 729-30.
[http://dx.doi.org/10.1097/JCP.0000000000000794]
[41]
Gupta N, Basu D. Does risperidone reduce concomitant substance abuse in cases of schizophrenia? Canadian J Psychiatry 2001; 46(9): 862-3.
[http://dx.doi.org/10.1177/070674370104600919]
[42]
Potvin S, Stip E, Roy JY. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 2004; 49(10): 711.
[http://dx.doi.org/10.1177/070674370404901020] [PMID: 15560324]
[43]
Sutter M, Walter M, Dürsteler KM, Strasser J, Vogel M. Psychosis after switch in opioid maintenance agonist and risperidone-induced pisa syndrome: Two critical incidents in dual diagnosis treatment. J Dual Diagn 2017; 13(2): 157-65.
[http://dx.doi.org/10.1080/15504263.2016.1269224] [PMID: 27935442]
[44]
Wayne D, Madigan T. Quetiapine and gabapentin dramatically improve treatment-resistant schizoaffective disorder in a patient with a long history of cocaine abuse. Addict Disord Their Treat 2004; 3(2): 83-6.
[http://dx.doi.org/10.1097/00132576-200406000-00005]
[45]
Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: A case report. Int J Psychiatry Med 2003; 33(1): 85-9.
[http://dx.doi.org/10.2190/WM5V-D9Y2-2HYW-VGWX] [PMID: 12906345]
[46]
Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophr Res 2018; 194: 32-8.
[http://dx.doi.org/10.1016/j.schres.2017.03.030] [PMID: 28351544]
[47]
Schnell T, Koethe D, Krasnianski A, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study. Am J Addict 2014; 23(3): 308-12.
[http://dx.doi.org/10.1111/j.1521-0391.2014.12126.x] [PMID: 24628830]
[48]
Skryabin VY, Vinnikova MA, Ezhkova EV, Titkov MS, Bulatova RA. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: The results of a randomized comparative study. J Addict Dis 2021; 39(4): 513-25.
[http://dx.doi.org/10.1080/10550887.2021.1905589] [PMID: 33832406]
[49]
Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. J Clin Psychopharmacol 2006; 26(1): 9-12.
[http://dx.doi.org/10.1097/01.jcp.0000194624.07611.5e] [PMID: 16415698]
[50]
Brunette MF, Akerman SC, Dawson R, O’Keefe CD, Green AI. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol 2016; 53: 45-50.
[http://dx.doi.org/10.1016/j.alcohol.2016.02.006] [PMID: 27256763]
[51]
Beresford T, Buchanan J, Thumm EB, Emrick C, Weitzenkamp D, Ronan PJ. Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in Schizophrenia and comorbid cocaine dependence. J Clin Psychopharmacol 2017; 37(6): 657-63.
[http://dx.doi.org/10.1097/JCP.0000000000000789] [PMID: 28984746]
[52]
Bruno A, Romeo VM, Pandolfo G, Scimeca G, Zoccali RA, Muscatello MRA. Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: An 8-week, open-label, uncontrolled, preliminary study. Subst Abus 2014; 35(2): 119-21.
[http://dx.doi.org/10.1080/08897077.2013.814615] [PMID: 24821345]
[53]
Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998; 33(1-2): 95-101.
[http://dx.doi.org/10.1016/S0920-9964(98)00062-0] [PMID: 9783349]
[54]
Cuomo I, Kotzalidis GD, de Persis S, et al. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat 2018; 14: 1645-56.
[http://dx.doi.org/10.2147/NDT.S171002] [PMID: 29950846]
[55]
Levin FR, Evans SM, Coomaraswammy S, Collins ED, Regent N, Kleber HD. Flupenthixol treatment for cocaine abusers with schizophrenia: A pilot study. Am J Drug Alcohol Abuse 1998; 24(3): 343-60.
[http://dx.doi.org/10.3109/00952999809016902] [PMID: 9741939]
[56]
Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001; 21(4): 217-21.
[http://dx.doi.org/10.1016/S0740-5472(01)00205-7] [PMID: 11777671]
[57]
Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial. Curr Med Res Opin 2006; 22(7): 1277-85.
[http://dx.doi.org/10.1185/030079906X112561] [PMID: 16834826]
[58]
Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006; 51(8): 531-9.
[http://dx.doi.org/10.1177/070674370605100808] [PMID: 16933590]
[59]
Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002; 47(7): 671-5.
[http://dx.doi.org/10.1177/070674370204700710] [PMID: 12355680]
[60]
van Nimwegen-Campailla L, van Beveren N, Laan W, van den Brink W, Linszen D, de Haan L. Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis. Pharmacopsychiatry 2010; 43(7): 281.
[http://dx.doi.org/10.1055/s-0030-1263172] [PMID: 20839158]
[61]
Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 2007; 16(4): 260-8.
[http://dx.doi.org/10.1080/10550490701389658] [PMID: 17661193]
[62]
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia. J Nerv Ment Dis 2015; 203(7): 486-92.
[http://dx.doi.org/10.1097/NMD.0000000000000317] [PMID: 26075840]
[63]
Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005; 193(6): 379-86.
[http://dx.doi.org/10.1097/01.nmd.0000165089.14736.bf] [PMID: 15920378]
[64]
van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: A double-blind randomized controlled trial. Can J Psychiatry 2008; 53(6): 400-5.
[http://dx.doi.org/10.1177/070674370805300610] [PMID: 18616861]
[65]
Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26(2): 441-9.
[http://dx.doi.org/10.1093/oxfordjournals.schbul.a033464] [PMID: 10885642]
[66]
Gerra G, Di Petta G, D’Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol 2007; 30(3): 127-35.
[http://dx.doi.org/10.1097/wnf.0b013e31803354f6] [PMID: 17545747]
[67]
Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone. Schizophr Res 2003; 60(1): 81-5.
[http://dx.doi.org/10.1016/S0920-9964(02)00231-1] [PMID: 12505141]
[68]
Machielsen M, Beduin AS, Dekker N, et al. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol 2012; 26(1): 189-95.
[http://dx.doi.org/10.1177/0269881111408957] [PMID: 21768161]
[69]
Stuyt EB, Sajbel TA, Allen MH. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 2006; 15(2): 166-73.
[http://dx.doi.org/10.1080/10550490500528613] [PMID: 16595355]
[70]
Thomas-Brown PL, Martin JS, Sewell CA, Abel WD, Gossell-Williams MD. Risperidone provides better improvement of sleep disturbances than haloperidol therapy in schizophrenia patients with Cannabis-Positive urinalysis. Front Pharmacol 2018; 9: 769.
[http://dx.doi.org/10.3389/fphar.2018.00769] [PMID: 30072895]
[71]
Zhornitsky S, Stip E, Desfossés J, et al. Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: A 12-week, pilot, case-control trial with quetiapine. Front Psychiatry 2011; 2: 22.
[http://dx.doi.org/10.3389/fpsyt.2011.00022] [PMID: 21629845]
[72]
Szerman N, Basurte-Villamor I, Vega P, et al. Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: A multicentre, observational study. Drugs Real World Outcomes 2020; 7(1): 75-83.
[http://dx.doi.org/10.1007/s40801-020-00178-8] [PMID: 32026379]
[73]
Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32(4): 637-43.
[http://dx.doi.org/10.1093/schbul/sbl003] [PMID: 16782758]
[74]
Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(4): 984-8.
[http://dx.doi.org/10.1016/j.pnpbp.2008.01.009] [PMID: 18262321]
[75]
Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. J Psychopharmacol 2014; 28(7): 633-42.
[http://dx.doi.org/10.1177/0269881114527357] [PMID: 24646809]
[76]
Taylor S, Annand F, Burkinshaw P, et al. Dependence and withdrawal associated with some prescribed medicines An evidence review. London, England. Public Health 2019; pp. 89-92.
[77]
Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol 2005; 25(4): 363-6.
[http://dx.doi.org/10.1097/01.jcp.0000169419.38899.5b] [PMID: 16012280]
[78]
McHugh R, Votaw V, Sugarman D, Greenfield S. Sex and gender differences in substance use disorders. Clin Psychol Rev 2018; (66): 12-23.
[http://dx.doi.org/10.1016/j.cpr.2017.10.012]
[79]
Barajas A, Ochoa S, Obiols JE, Lalucat-Jo L. Gender differences in individuals at high-risk of psychosis: A comprehensive literature review. Sci World J 2015; 2015: 430735.
[80]
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European monitoring centre for drugs and drug addiction European Drug Report 2021: Trends and Developments 2021.
[81]
Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: Results from the GBD 2010 study. PLoS One 2013; 8(10): e76635.
[http://dx.doi.org/10.1371/journal.pone.0076635] [PMID: 24204649]
[82]
Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry 2019; 6(5): 427-36.
[http://dx.doi.org/10.1016/S2215-0366(19)30048-3] [PMID: 30902669]
[83]
Ortiz-Medina MB, Perea M, Torales J, et al. Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry 2018; 64(7): 690-704.
[http://dx.doi.org/10.1177/0020764018801690] [PMID: 30442059]
[84]
Lieberman JA. Dopamine partial agonists: A new class of antipsychotic. CNS Drugs 2004; 18(4): 251-67.
[http://dx.doi.org/10.2165/00023210-200418040-00005] [PMID: 15015905]
[85]
Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 2016; 15(10): 1329-47.
[http://dx.doi.org/10.1080/14740338.2016.1201475] [PMID: 27347638]
[86]
Moreira FA, Dalley JW. Dopamine receptor partial agonists and addiction. Eur J Pharmacol 2015; 752: 112-5.
[http://dx.doi.org/10.1016/j.ejphar.2015.02.025] [PMID: 25724788]
[87]
Martinotti G, Orsolini L, Fornaro M, et al. Aripiprazole for relapse prevention and craving in alcohol use disorder: Current evidence and future perspectives. Expert Opin Investig Drugs 2016; 25(6): 719-28.
[http://dx.doi.org/10.1080/13543784.2016.1175431] [PMID: 27098451]
[88]
Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017; 7(1): 29-41.
[http://dx.doi.org/10.1177/2045125316672136] [PMID: 28101322]
[89]
Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z. Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Psychopharmacology (Berl) 2013; 226(2): 285-93.
[http://dx.doi.org/10.1007/s00213-012-2906-7] [PMID: 23138433]
[90]
Rodriguez Cruz J, Sahlsten Schölin J, Hjorth S. Case report: Cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction. Front Psychiatry 2021; 12: 727666.
[http://dx.doi.org/10.3389/fpsyt.2021.727666] [PMID: 34489766]
[91]
Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal. Ther Adv Psychopharmacol 2014; 4(5): 198-219.
[http://dx.doi.org/10.1177/2045125314540297] [PMID: 25360245]
[92]
Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn 2012; 8(1): 50-61.
[http://dx.doi.org/10.1080/15504263.2012.647345] [PMID: 22754405]
[93]
Starr HL, Bermak J, Mao L, Rodriguez S, Alphs L. Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study. Schizophr Res 2018; 194: 39-46.
[http://dx.doi.org/10.1016/j.schres.2017.05.005] [PMID: 28601497]
[94]
Quattrone D, Ferraro L, Tripoli G, et al. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study. Psychol Med 2020; 51(8): 1-9.
[PMID: 32183927]
[95]
Sacchetti E, Grunze H, Leucht S, Vita A. Long-acting injection antipsychotic medications in the management of schizophrenia. Evidence-based Psychiatric Care 2015; (1): 27-36.
[96]
Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: Consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med 2012; 13(1): 26-34.
[http://dx.doi.org/10.5811/westjem.2011.9.6866] [PMID: 22461918]
[97]
Andrezina R, Marcus RN, Oren DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study. Curr Med Res Opin 2006; 22(11): 2209-19.
[http://dx.doi.org/10.1185/030079906X148445] [PMID: 17076982]
[98]
Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13: 757-77.
[http://dx.doi.org/10.2147/TCRM.S117321] [PMID: 28721057]
[99]
Fluyau D, Mitra P, Lorthe K. Antipsychotics for amphetamine psychosis. A systematic review. Front Psychiatry 2019; 10: 740.
[http://dx.doi.org/10.3389/fpsyt.2019.00740] [PMID: 31681046]
[100]
Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1375-85.
[http://dx.doi.org/10.1016/j.pnpbp.2008.02.008] [PMID: 18394768]
[101]
Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: A systematic review of head-head comparisons. J Psychopharmacol 2012; 26(5): 15-26.
[http://dx.doi.org/10.1177/0269881111424929] [PMID: 22057019]
[102]
Allain H, Dautzenberg PH, Maurer K, Schuck S, Bonhomme D, Gérard D. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl) 2000; 148(4): 361-6.
[http://dx.doi.org/10.1007/s002130050064] [PMID: 10928308]
[103]
Paris G, Bighelli I, Deste G, et al. Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. Schizophr Res 2021; 229: 3-11.
[http://dx.doi.org/10.1016/j.schres.2021.01.021] [PMID: 33607608]
[104]
Sanford M, Scott LJ. Intramuscular aripiprazole: A review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 2008; 22(4): 335-52.
[http://dx.doi.org/10.2165/00023210-200822040-00005] [PMID: 18336061]
[105]
Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2018; 1(1): CD008074.
[http://dx.doi.org/10.1002/14651858.CD008074.pub2] [PMID: 29308601]
[106]
Fagiolini A, De Filippis S, Azzarelli O, et al. Intramuscular aripiprazole for the treatment of agitation in schizophrenia and bipolar disorder: From clinical research to clinical practice. J Psychopathol 2013; 19(1): 34-41.
[107]
Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27(2): 171-6.
[http://dx.doi.org/10.1097/JCP.0b13e318033bd5e] [PMID: 17414241]
[108]
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68(1): 111-9.
[http://dx.doi.org/10.4088/JCP.v68n0115] [PMID: 17284138]
[109]
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127(1-3): 83-92.
[http://dx.doi.org/10.1016/j.schres.2010.11.020] [PMID: 21257294]
[110]
Abdel-Baki A, Medrano S, Maranda C, et al. Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol 2020; 35(4): 221-8.
[http://dx.doi.org/10.1097/YIC.0000000000000310] [PMID: 32282448]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy